학술논문
Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial
Document Type
Article
Author
Gladish, Deborah; Myers, Karen; Kuramochi, Yuki; Sewell, Christina; Balog, Craig; Kosty Sweeny, Denise; Kandrac, Jill; Spencer, Stephanie; Goyanes, Alice; Sahoo, Debasis; Dugar, Siddharth; Aguillon Prada, Robier; Nichols, Dave; Celiberti, Jeannie; Partisano, Annie; Fang, Fang; Coehlo, Jennifer; Perrin, Randy; Mandell, Brian; Gordon, Steven; Wiedemann, Herbert; Young, James; Greer, Joan; Ho, Ai-Chen; Ladd, Any; Mihalick, Virginia; Montpetit, Alison; O'Brine, Joyce; Owen, Catherine; Pal, Mary; Priday, Anna; Raj Sedhai, Yub; Wohlford, George; Hummel, Nicole; Korbee, Leslie; Cremer, Paul C ; Abbate, Antonio; Hudock, Kristin; McWilliams, Carla; Mehta, Jinesh; Chang, Steven Y; Sheng, Calvin C; Van Tassell, Benjamin; Bonaventura, Aldo; Vecchié, Alessandra; Carey, Brenna; Wang, Qiuqing; Wolski, Katherine E; Rajendram, Prabalini; Duggal, Abhijit; Wang, Tisha S; Paolini, John F; Trapnell, Bruce C
Source
In The Lancet Rheumatology June 2021 3(6):e410-e418
Subject
Language
ISSN
2665-9913